Last updated on December 2018

S0820 Adenoma and Second Primary Prevention Trial


Brief description of study

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer.

Detailed Study Description

The purpose of this study is to assess whether eflornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate of high risk adenoma or second primary colorectal cancer in Stage 0, I II and III colon cancer patients. The primary hypothesis will test the main effect of each agent, as well as the comparison of placebo alone to the combination of sulindac and eflornithine.

Clinical Study Identifier: NCT01349881

Contact Investigators or Research Sites near you

Start Over

Patricia N. O'Kane, B.S.

Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, OH United States
2.11miles
  Connect »

Jennifer A. Dorth

UH Seidman Cancer Center at Saint John Medical Center
Westlake, OH United States
6.58miles
  Connect »

Jennifer A. Dorth

UHHS-Westlake Medical Center
Westlake, OH United States
6.58miles
  Connect »

Jennifer A. Dorth

Southwest General Health Center Ireland Cancer Center
Middleburg Heights, OH United States
7.06miles
  Connect »

Jennifer A. Dorth

University Hospitals Parma Medical Center
Parma, OH United States
7.42miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.